Eisai and Biogen have recently reported long-term data on their therapy, Leqembi (lecanemab), which showed that it is able to reduce cognitive decline without increased safety risk. Eli Lilly also ...
Taylor Tepper covered banking, investing and pretty much everything else in personal finance for more than a decade, with his work appearing in the New York Times, Fortune and MONEY magazine, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback